Superhance on the ASK
Superhance® 680 is a small molecule fluorescent in vivo blood pool imaging agent. Superhance 680 enables imaging of circulation, blood vessels, vasculature, vascular leak, including that associated with early oncologic and opthalmologic lesions.
Products and catalog numbers
|Product||Catalog Number||Ex/Em wavelength (nm)||Molecular weight (g/mol)||Validated Experiments||Applications|
|Superhance 680||NEV10116||675/692||~ 1540||In vivo||Vascular|
Using Superhance in vivo
The generally recommended procedure for in vivo imaging with Superhance 680 is administration via tail vein injection and imaging 0.5 – 24 hours post-injection.
- For Acute Edema, we recommend imaging 3 hours post injection.
- For IVM: 5-15 min post injection
|Product||Route of Injection||Mouse Dose (25 g)||Rat Dose (250 g)||Blood t 1/2||Tissue t 1/2||Optimal imaging time||Optimal Re-injection Time (complete clearance)||Route of Metabolism/ background tissue||FMT& IVIS settings|
|Superhance 680||IV||4 nmol (150 uL)||12-40 nmol||1.5 h||5 h||3 h (1-3 h)||96 h||Bladder||FMT 680/700
To determine the optimal imaging timepoint relative to agent injection, we imaged 4T1 tumor-bearing mice at different times post-Superhance 680 injection (Figure 1). Whole body images at 3 h post-injection (Figure 1A) reveal signal throughout the body (including bladder, intestines, liver, and heart) as well as in the tumor periphery.
Figure 1. Imaging tumors. FMT and planar images show the patterns of fluorescence that occur in animals bearing tumor masses on the upper mammary fat pads. A) Whole body signal by FMT imaging. B) FMT imaging showing only tumor region fluorescence over time. Inset panels represent surface fluorescence detected by planar imaging.
Application notes and posters
- Application note: Comparison of PerkinElmer Vascular Pre-clinical Fluorescent Imaging Agents in Oncology and Inflammation Research
Please visit our Citations Library for references using Genhance on the IVIS or on the FMT.